Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 27;1(3):265-269.
doi: 10.1182/bloodadvances.2016000034.

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Kara L Davis  1 , Crystal L Mackall  1   2
Affiliations

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Kara L Davis et al. Blood Adv. .

Abstract

Publisher's Note: This article has a companion Point by Jabbour and Kantarjian. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.L.M. has patents/royalties from Juno Therapeutics. K.L.D. declares no competing financial interests.

Figures

Figure 1.
Figure 1.
Overview of administration and kinetics of CAR T cells. (A) Overview of CAR T-cell manufacturing and administration. (B) Impact of CAR T-cell costimulatory domain (CD28 or 4-1BB) on kinetics and duration of CAR T cells.
See this image and copyright information in PMC

References

    1. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753. - PMC - PubMed
    1. Magrath I. Bone marrow transplantation for leukaemia: a lame stalking horse for use of high-technology medical care. Lancet. 1995;345(8950):601-602. - PubMed
    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528. - PMC - PubMed
    1. Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99(7):1212-1219. - PMC - PubMed
    1. Gore L, Locatelli F, Zugmaier G, et al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia [abstract]. Blood. 2014;124(21). Abstract 3703.